Pfizer Inc. $PFE Shares Bought by Truvestments Capital LLC

Truvestments Capital LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,780 shares of the biopharmaceutical company’s stock after buying an additional 1,751 shares during the quarter. Truvestments Capital LLC’s holdings in Pfizer were worth $425,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in PFE. Pacer Advisors Inc. lifted its holdings in Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after buying an additional 17,957,928 shares in the last quarter. Nuveen LLC acquired a new stake in Pfizer during the 1st quarter worth approximately $389,861,000. Starboard Value LP acquired a new stake in Pfizer during the 4th quarter worth approximately $407,730,000. Goldman Sachs Group Inc. lifted its holdings in Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after buying an additional 9,041,990 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company’s stock worth $254,574,000 after buying an additional 7,581,030 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 0.6%

Shares of Pfizer stock opened at $25.08 on Thursday. The company has a fifty day simple moving average of $24.76 and a 200-day simple moving average of $24.40. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market cap of $142.57 billion, a price-to-earnings ratio of 13.34, a PEG ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the prior year, the business posted $0.60 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio is presently 91.49%.

Analysts Set New Price Targets

Several research firms have commented on PFE. Bank of America boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Wolfe Research boosted their price target on shares of Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a report on Wednesday, April 30th. Redburn Atlantic lowered their price target on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating for the company in a report on Wednesday, April 30th. The Goldman Sachs Group boosted their price target on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Finally, HSBC lowered their price target on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a report on Monday, May 19th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.